Zuoqing San for ulcerative colitis trial
Part of Digestive system clinical trials.
This trial tests if a traditional Chinese medicine formula, Zuoqing San, can help people with mild to moderate ulcerative colitis. It aims to see if the treatment can improve symptoms and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with ulcerative colitis.
- Your ulcerative colitis must be mild or moderate in severity.
- You cannot have severe liver, kidney, heart, or brain disease.
- You cannot be allergic to any Chinese medicine ingredients.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests if a live bacterial powder (SK08) can help people with active mild to moderate ulcerative colitis. It aims to see if it improves symptoms and is safe to take.
This trial tests whether adding a probiotic supplement and trace elements to your current treatment helps manage mild to moderate ulcerative colitis. It aims to see if these additions can improve symptoms and quality of life.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This trial compares two medicines — etrasimod (a new pill) and mesalazine (a standard anti-inflammatory) — to see which works better and is safer for Chinese adults with active ulcerative colitis. Participants will receive one of the two treatments, and the study aims to find if the newer drug offers more benefit.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.